Search
Enrofloxacin
go.drugbank.com/drugs/DB11404InvestigationalVet approvedEnrofloxacin is an antibiotic agent from the fluoroquinolone family produced by the Bayer Corporation. Enrofloxacin is approved by the FDA for its veterinary use.
Leukotriene C4
go.drugbank.com/drugs/DB08855Experimental(From Dictionary of Prostaglandins and Related Compounds, 1990)
Synonyms: (R-(R*,S*-(E,E,Z,Z)))-N-(S-(1-(4-Carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraenyl)-N-L-gamma-glutamyl-L-cysteinyl)glycine, L-γ-glutamyl-S-[(1R,2E,4E,6Z,9Z)-1-[(1S)-4-carboxy-1-hydroxybutyl]pentadeca-2,4,6,9-tetraen-1-yl]-L-cysteinylglycineDasotraline
go.drugbank.com/drugs/DB12305InvestigationalDasotraline is a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI) that is under investigation for the treatment of Binge Eating Disorder, Adult Attention Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder, ...
Bafilomycin A1
go.drugbank.com/drugs/DB06733ExperimentalThe bafilomycins refer to a category of toxic macrolide antibiotics that are derivatives of Streptomyces griseus. These compounds all appear in the same fermentation and have similar biological activity. Bafilomycins are specific inhibit...
QR-334
go.drugbank.com/drugs/DB05473ExperimentalNo pharmaceutical interventions currently exist to treat sialorrhea.
Mefloquine
go.drugbank.com/drugs/DB00358Approved[L30618] Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa.
Plerixafor
go.drugbank.com/drugs/DB06809ApprovedInvestigational[A7117,L45678] It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma to stimulate their immune system.
Metreleptin
go.drugbank.com/drugs/DB09046ApprovedInvestigationalMetreleptin is produced in _E. coli_ and differs from native human leptin by the addition of a methionine residue at its amino terminus.
Synonyms: N-MethionylleptinDaratumumab
go.drugbank.com/drugs/DB09331ApprovedInvestigationalThis approval was based on results from the Phase 3 PERSEUS study, which demonstrated significant improvement in progression-free survival and higher rates of minimal residual disease (MRD) negativity